Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL003 Angiogenesis Assessment in Critical Limb Ischemia
NCT05968118Phase 3Unknown
- Sponsor
- Northland Biotech
- Start
- Jul 2022
- Primary completion
- Jul 2023
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 3 trial of naked plasmid encoding human hepatocyte growth factor in critical limb ischemia (CLI), sponsored by Northland Biotech. Status: unknown.
02
Drugs
naked plasmid encoding human hepatocyte growth factor
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT05968118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05968118.